UNSPSC 51422505: Amebucort

This classification denotes a therapeutic glucocorticoid with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YRF8G0G0F, chemically known as 11 beta,17,21-trihydroxy-6 alpha-methylpregn-4-ene-3,20-dione 21-acetate 17-butyrate but generally known as amebucort, which bears US NIH Compound Identifier 3086167. European Medicines Agency schedules Amebucort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05405MIG.

UNSPSC 51422505 Amebucort is a Commodity code that does not match the work actually being solicited under it in recent state and local procurement. The recent opportunity on file shows Seminole County, Florida issuing an IFB for Naloxone and Safe Drug Deactivation Systems—a public health procurement entirely unrelated to Amebucort, a corticosteroid pharmaceutical product. The mismatch suggests either a tagging error in the source system or that this code does not reflect current state and local buying activity. No additional recent opportunities under this code are present in the source.

The single recent record naming this code shows Seminole County, Florida posting IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023 (an inconsistency in the source dates), seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with a one-year renewal option and requires vendors to comply with drug-free workplace certification, E-Verify requirements, and specific insurance coverage including workers' compensation and commercial general liability. FEMA funding introduces additional federal compliance obligations. Given the absence of supporting opportunities and the fundamental mismatch between the code's pharmaceutical scope and the recent health-systems procurement, pursuit under this code is not recommended without clarification from the source procurement system.